TY - JOUR
T1 - Aflibercept versus placebo in combination with fluorouracil, leucovorin and irinotecan in the treatment of previously treated metastatic colorectal cancer: prespecified subgroup analyses from the VELOUR trial
AU - Tabernero, Josep
AU - Van Cutsem, Eric
AU - Lakomy, Radek
AU - Prausova, Jana
AU - Ruff, Paul
AU - Van Hazel, Guy A
AU - Moiseyenko, Vladimir M
AU - Ferry, David R
AU - McKendrick, Joseph
AU - Soussan-Lazard, Karen
AU - Chevalier, Soazig
AU - Allegra, Carmen J
PY - 2014
Y1 - 2014
N2 - The antiangiogenic agent aflibercept (ziv-aflibercept in the United States) in combination with 5-fluorouracil, leucovorin and irinotecan (FOLFIRI) significantly improved survival in a phase III study of patients with metastatic colorectal cancer (mCRC) previously treated with an oxaliplatin-based regimen. In the present analysis, outcomes were evaluated in prespecified subgroups to assess the consistency of the treatment effect.
AB - The antiangiogenic agent aflibercept (ziv-aflibercept in the United States) in combination with 5-fluorouracil, leucovorin and irinotecan (FOLFIRI) significantly improved survival in a phase III study of patients with metastatic colorectal cancer (mCRC) previously treated with an oxaliplatin-based regimen. In the present analysis, outcomes were evaluated in prespecified subgroups to assess the consistency of the treatment effect.
UR - http://www.sciencedirect.com/science/article/pii/S0959804913008538
U2 - 10.1016/j.ejca.2013.09.013
DO - 10.1016/j.ejca.2013.09.013
M3 - Article
VL - 50
SP - 320
EP - 331
JO - European Journal of Cancer
JF - European Journal of Cancer
SN - 0959-8049
IS - 2
ER -
